Keyphrases
PrimPol
100%
Bulky DNA Adducts
100%
Acute Myeloid Leukemia
100%
Azacitidine
100%
Molecular Signature
100%
Vorinostat
100%
Gap Formation
100%
Hypertranscription
100%
Replication Stress
100%
Homologous Recombination
100%
In Cancer
100%
Oncogene
75%
Bulky Adduct
42%
RAD51
42%
Overall Survival
37%
Mammalian Cells
28%
Bromodomain Inhibitors
25%
Clinical Activity
25%
Replication Stress Response
25%
Targeted Cancer Treatment
25%
Genomic Instability
25%
Replication Fork Progression
25%
Bromodomain
25%
Mechanistic Understanding
25%
Targeted Cancer Therapy
25%
Oncogenic Signaling
25%
Global Transcription
25%
Cellular Response
25%
R-loops
25%
Transcription Activity
25%
EXO1
14%
Post-replicative Gap Repair
14%
BPDE-DNA Adducts
14%
Stalled Replication Fork
14%
Resection
14%
Fork Stalling
14%
Primase
14%
Stalled Forks
14%
Sister Chromatid Exchange
14%
DNA Damage Tolerance
14%
Genetic Recombination
14%
Double-strand Breaks
14%
MRE11
14%
Post-replication Repair
14%
Rational Utilization
12%
CDKN2A mutation
12%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
12%
Clinical Response
12%
Older Patients
12%
De Novo Acute Myeloid Leukemia
12%
Biochemistry, Genetics and Molecular Biology
Oncogene
100%
DNA Adduct
100%
Azacitidine
100%
Transcription
100%
Homologous Recombination
100%
Myeloid
100%
Bromodomain
66%
RAD51
42%
Overall Survival
37%
R-Loop
33%
Genome Instability
33%
DNA Damage
14%
Sister Chromatid Exchange
14%
Primase
14%
Genetic Recombination
14%
DNA RNA Hybridization
14%
Next Generation Sequencing
12%
IDH1
12%
Progenitor Cell
12%
Histone Deacetylase
12%
Cell Cycle Checkpoint
12%
Cell Cycle Arrest
12%
Immunophenotyping
12%
Medicine and Dentistry
Azacitidine
100%
Molecular Diagnosis
100%
Vorinostat
100%
Acute Myeloid Leukemia
100%
Homologous Recombination
100%
DNA Adduct
100%
Overall Survival
37%
Mammalian Cell
28%
Genetic Recombination
14%
Sister Chromatid Exchange
14%
DNA Damage
14%
DNA RNA Hybridization
14%
Primase
14%
Surgery
14%
Cell Cycle Checkpoint
12%
Immunophenotyping
12%
Myelodysplastic Syndrome
12%
Progenitor Cell
12%
Monotherapy
12%
Histone Deacetylase Inhibitor
12%
Next Generation Sequencing
12%
Cell Cycle Arrest
12%